Abstract. The benefits of adjuvant intraoperative radiotherapy (IORT) for resectable gastric cancer have been extensively studied, but data on the survival rate remains equivocal. A meta-analysis was performed of the studies involving the use of IORT for resectable gastric cancer using web-based databases. Hazard ratios (HRs) describing the impact of adjuvant IORT on the overall survival (OS) rate and locoregional control were extracted directly from the original studies or calculated from survival curves. A meta-analysis of four studies that provided OS data revealed that IORT had no significant impact on OS [HR, 0.97; 95% confidence interval (CI), 0.75-1.26; P= 0.837]. In the three studies testing the efficacy of IORT for OS in the subgroup of patients with stage III disease, there was a significantly improved OS (HR, 0.60; 95% CI, 0.40-0.89; P= 0.011). Significant locoregional control improvement was observed in the four studies that provided locoregional control data (HR 0.40; 95% CI, 0.26-0.62; P<0.001). This meta-analysis showed a statistically significant locoregional control benefit with the addition of IORT in patients with resectable gastric cancer. In addition, the available data revealed that adjuvant IORT may provide promising results on the survival rate for the subgroup of patients with stage III disease. Further study is required to optimize the implementation of adjuvant IORT for gastric cancer with regard to patient selection and integration with systemic therapy.
Introduction
Despite advances in surgical techniques, the outcome of patients with locally advanced gastric cancer following surgery remains poor (1) . Locoregional recurrence is the main pattern of failure in gastric cancer patients treated with complete resection (2, 3) . Although the efficacy of postoperative chemoradiotherapy following radical surgery for locally advanced gastric cancer has been confirmed in the INT-0116 trial (4), the prognosis remains suboptimal. Theoretically, a greater radiation dose may provide a higher tumor control. However, owing to the dose-limiting surrounding tissues in the planning treatment volume, including small intestine, pancreas, bile ducts and spinal cord, the higher doses that are necessary for disease control cannot be safely delivered with conventional external-beam radiotherapy (EBRT) (5) . Intraoperative radiotherapy (IORT) allows the delivery of a boost of radiation to a localized area in a single fraction without affecting the surrounding tissues (6) . An IORT boost component has also been included in the context of surgical resection, adjuvant EBRT and chemotherapy, with acceptable tolerance and improved locoregional control (7, 8) .
Although the efficacy of IORT for locally advanced gastric cancer has been previously addressed in several studies and suggests that the addition of IORT may increase the locoregional control and thereby may improve the overall survival (OS), the results from all available studies have been equivocal (9-11). To determine whether there is a benefit of IORT for resectable gastric cancer, a meta-analysis was performed of studies that focused on this topic.
Materials and methods
Search strategy and selection criteria. A bibliographical study was performed using the PubMed, Web of knowledge and Embase electronic databases. The following medical subject headings, keywords and text words were used: i) Gastric or stomach, and cancer, carcinoma or adenocarcinoma; and ii) intraoperative radiotherapy or IORT. The search included the studies that were published between January, 1990 and July, 2013. The computer search was supplemented with a manual search of the reference lists from all available review studies, primary studies, meetings abstracts and bibliographies of books, in order to identify other studies that were not found Benefits from adjuvant intraoperative radiotherapy treatment for gastric cancer: A meta-analysis during the computer search. When the results of a single study were reported in more than one publication, only the most recent and complete data were included in the meta-analysis. The potentially eligible studies were retrieved and a full-text analysis was performed. Only the studies that included OS and/or the locoregional control rate comparison between the patients with histology-proven cancer of the stomach, assigned to surgery alone (observation arm) or to surgery plus IORT (study arm) were included in the review process. EBRT and chemotherapy were administered to the patients in both arms.
Data extraction. Data were carefully extracted independently by two investigators (W.W. Yu and Y.M. Guo) according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (12) . The following information was extracted from each study: First author's name, year of publication, study design, number of patients, rates of dissections and endpoints reported (OS and locoregional control rates).
Hazard ratios (HRs) for the OS and locoregional control rates were extracted directly from the original studies or were estimated indirectly by reading off survival curves as suggested by Tierney et al (13) . In summary, when the estimated HR and its standard error were described in the publications, these values were obtained directly; when these statistical variables were not provided explicitly in a study they were calculated directly using two of the following parameters: The confidence interval (CI) for the HR, the log-rank statistic, the P-value or the O-E statistic (difference between numbers of observed and expected events). When those data were not available, the following were studied: The total number of events, the number of patients at risk in each group and the log-rank statistic or its P-value, allowing calculation of an approximation of the HR estimate. When the only available data were in the form of graphical representations, they were calculated from Kaplan-Meier survival curves. The Kaplan-Meier curves were read by two investigators using the Engauge Digitizer 4.1 version software (Mark Mitchell, Boston, MA, USA) independently to reduce the inaccuracy in the extracted survival rates. The HRs for OS were also extracted for the patient subgroups (including patients with stage III) whenever possible.
Statistical analysis. The heterogeneity was formally investigated by means of Cochrane Q statistic and I 2 statistic. For the Q statistic, the heterogeneity when P<0.1 was considered to indicate a statistically significant difference. The I 2 statistic, which is the proportion of the total variation among the studies that is likely to be explained by between-study heterogeneity rather than chance (14) , is reported. Substantial heterogeneity exists when I 2 >50%. When the hypothesis of homogeneity was not rejected, a fixed-effects model was used. Otherwise, the random-effects model was used (15) . By convention, the impact of IORT on the OS or locoregional control rates was considered to indicate a statistical significance if the 95% CI for the overall HR did not overlap 1. The evidence of publication bias was evaluated by the funnel plot with the test of Begg and Mazumdar (16) and the linear regression asymmetry test of Egger et al (17) . For these analyses, P<0.05 was considered to indicate statistically significant publication bias. All statistical analyses were performed by the STATA 12.0 software (Stata Corp., College Station, TX, USA).
Results

Trial selection and characteristics of the included studies.
A total of 607 relevant studies were collected. Subsequent to the exclusion of the duplicate references by the 'find duplicates' function of EndNote X3, there were 173 unique studies. Following a review of each title and abstract, 12 studies meeting the eligibility criteria were identified. A careful examination of these full studies led to the exclusion of four studies: The updated results from one study were available in a separate publication (7) and four were excluded as they did not meet the inclusion criteria (18) (19) (20) . Thus, a total of eight studies were included in the meta-analysis (8) (9) (10) (11) (21) (22) (23) (24) (Fig. 1) .
Study characteristics. The details regarding the eight studies included in the analysis are summarized in Table I . The OS data for all patients in trials were available for four studies (8, 9, 11, 24) . Three studies provided the OS data for the subgroup of patients with stage III disease, and they all tested surgery followed by adjuvant IORT against surgery alone (21) (22) (23) . The locoregional control rate was provided in the four studies (8, 10, 11, 24) .
Meta-analysis findings.
The meta-analysis of the four studies that provided data on OS revealed that IORT had no significant impact in OS. The pooled HR was 0.97 (95% CI, 0.75-1.26; Z= 0.21; P= 0.837), without any evidence of heterogeneity (P=0.644) (Fig. 2) . In the three studies testing the efficacy of IORT for OS in the subgroup of patients with stage III disease, there was a significantly improved OS (HR, 0.60; 95% CI; 0.40-0.89; Z=2.53; P=0.011) (Fig. 3) . The significant locoregional control improvement was observed in the four studies that provided locoregional control data, and the combined HR was 0.40 (95% CI, 0.26-0.62; Z=4.18; P<0.001), without heterogeneity (P= 0.516) (Fig. 4) . For all eight studies, there was no evidence found of publication bias using the Egger's test (P=0.969) and Begg's test (P=1.0). The shape of the funnel plot for the pooled HR appeared to be symmetrical (Fig. 5) .
Discussion
To the best of our knowledge, the present study represents the first specific meta-analysis examining the impact of IORT for patients with resectable gastric carcinoma. Although meta-analysis based on individual data is considered to be the gold standard, a meta-analysis based on the studies was still used in the present study, as individual patient data were difficult to access in the various studies published over a 20-year period. By aggregating data from four eligible studies, it was found that the use of IORT had no significant affect on OS. Notably, when the focus was on the subgroup of patients with stage III disease, it was found that the use of IORT was associated with a clear reduction in the risk of mortality from any cause. Furthermore, the combined HR for the four eligible studies that provided locoregional control data suggested that the use of IORT was associated with a significant improvement in the locoregional control.
It is well known that local control by radiation for subclinical disease is a function of radiation dose (25) . Thus, using a greater biological-radiotherapy dose could further improve the locoregional control of gastric cancer following complete surgical resection (26) . However, the radiation dose to the intra-abdominal structures is usually limited to 45 Gy due to the adjacent dose-limiting structures. However, this dose may not be sufficient for the eradication of the subclinical residual disease (27) . Significantly increasing the EBRT dose to the surgical bed and regional nodal areas is not acceptable when using conventional radiotherapy. IORT involves the administration of large single doses of radiation directly to surgically Figure 2 . Fixed-effects meta-analysis of the impact of adjuvant IORT on the overall survival rate for the entire patients in the four eligible studies. HR, hazard ratio; CI, confidence interval; IORT, intraoperative radiotherapy; EBRT, external-beam radiotherapy; CRT, chemoradiation; S, surgery. (23) 1995 No reported S + IORT (28) (29) (30) (31) (32) (33) (34) (35) No reported 77 OS (stage Ⅲ) S S, surgery; OS, overall survival; EBRT, external-beam radiotherapy; IORT, intraoperative radiation therapy; N pts, number of patients; CT, chemotherapy.
exposed tissues during the surgical procedures. Thereby, it offers the opportunity to deliver high doses of radiation to the primary tumor and regional nodal areas, whilst simultaneously minimizing the possibility of radiation toxicity for the surrounding normal-radiosensitive tissues. IORT has been explored in various types of malignancies, including gastric cancer, with studies focusing on the benefit for the locoregional control and survival rates (28) .
The findings in the present meta-analysis confirmed that the use of IORT was associated with a notable decrease in locoregional recurrence. In addition, the impact of IORT on OS reached statistical significance in the subgroup of patients with stage III disease, demonstrating that the use of IORT for locally advanced gastric cancer may yield promising results. However, the clear improvement of locoregional control did not translate into a benefit for OS in the entire cohort of patients. This may be due to the distant metastases offsetting the efficacy of IORT, emphasizing the requirement for more effective systemic therapies (8, 29, 30) . The advantage of IORT in OS may also be abolished by an increased perioperative mortality rate. Although the majority of studies did not investigate the impact of IORT on surgical complications, certain studies found an increase in the perioperative complications in conjunction with IORT (10, 20) . The surgical and radiotherapy techniques have improved over the last twenty years, and the higher mortality rate due to adjuvant IORT-associated toxicities most probably offset the benefit of IORT.
Particular limitations of the present meta-analysis should be taken into consideration when interpreting the findings. First, the meta-analysis was performed using study-level data. Patient-level data, if available, may provide more reliable findings. Although there was no statistical evidence of publication bias detected, this affect cannot be ruled out. Second, numerous studies that were selected for the meta-analysis were retrospective studies, which will inevitably have had selection bias. Third, the analysis was restricted to the published studies that were written in English, and several studies that met the eligibility criteria were excluded based on language criteria. Thus, the number of eligible studies was not sufficiently large for a comprehensive analysis.
In conclusion, the present meta-analysis suggests that the use of IORT for patients with resectable gastric cancer contributed to an increase in the locoregional control rate, but did not increase the OS rate. Further study is required to optimize the implementation of adjuvant IORT for gastric cancer with regard to patient selection and integration with systemic therapy.
